These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19682862)

  • 41. [The role of moxifloxacin in the prophylaxis of post-surgical endophthalmitis].
    Villalobos PA; Valle DD
    Arch Soc Esp Oftalmol; 2010 Oct; 85(10):323-4. PubMed ID: 21168055
    [No Abstract]   [Full Text] [Related]  

  • 42. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
    Kohno Y; Ohno H; Miyazaki Y; Higashiyama Y; Yanagihara K; Hirakata Y; Fukushima K; Kohno S
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4071-6. PubMed ID: 17709469
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Protective role of antibodies induced by Brucella melitensis B115 against B. melitensis and Brucella abortus infections in mice.
    Adone R; Francia M; Pistoia C; Petrucci P; Pesciaroli M; Pasquali P
    Vaccine; 2012 Jun; 30(27):3992-5. PubMed ID: 22521283
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
    Rustomjee R; Lienhardt C; Kanyok T; Davies GR; Levin J; Mthiyane T; Reddy C; Sturm AW; Sirgel FA; Allen J; Coleman DJ; Fourie B; Mitchison DA;
    Int J Tuberc Lung Dis; 2008 Feb; 12(2):128-38. PubMed ID: 18230244
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice.
    Ji B; Chauffour A; Robert J; Lefrançois S; Jarlier V
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3737-9. PubMed ID: 17664316
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of the latest fluoroquinolones against experimental Yersinia pestis.
    Steward J; Lever MS; Russell P; Beedham RJ; Stagg AJ; Taylor RR; Brooks TJ
    Int J Antimicrob Agents; 2004 Dec; 24(6):609-12. PubMed ID: 15555886
    [TBL] [Abstract][Full Text] [Related]  

  • 47. One-day application of topical moxifloxacin 0.5% to select for fluoroquinolone-resistant coagulase-negative Staphylococcus.
    He L; Ta CN; Miño de Kaspar H
    J Cataract Refract Surg; 2009 Oct; 35(10):1715-8. PubMed ID: 19781465
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Third- and fourth-generation fluoroquinolones: retrospective comparison of endophthalmitis after cataract surgery performed over 10 years.
    Jensen MK; Fiscella RG; Moshirfar M; Mooney B
    J Cataract Refract Surg; 2008 Sep; 34(9):1460-7. PubMed ID: 18721704
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ophthalmic moxifloxacin (Vigamox) and gatifloxacin (Zymar).
    Med Lett Drugs Ther; 2004 Mar; 46(1179):25-7. PubMed ID: 15057188
    [No Abstract]   [Full Text] [Related]  

  • 50. Doxycycline or moxifloxacin for the management of community-acquired pneumonia in the UK?
    Ludlam HA; Enoch DA
    Int J Antimicrob Agents; 2008 Aug; 32(2):101-5. PubMed ID: 18571380
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Brucella melitensis sternal osteomyelitis following median sternotomy.
    Chin YT; Krishnan M; Burns P; Qamruddin A; Hasan R; Dodgson AR
    J Infect Chemother; 2014 Sep; 20(9):574-6. PubMed ID: 24910374
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of fourth-generation fluoroquinolones on the healing rate of corneal erosions in an animal model.
    Barequet IS; Habot-Wilner Z; Lavinsky F; Ziv H; Belkin M; Rosner M
    Cornea; 2007 Jun; 26(5):606-9. PubMed ID: 17525660
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparison of therapeutic regimens containing moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% ophthalmic solution for surgical prophylaxis in patients undergoing LASIK or LASEK.
    Durrie DS; Trattler W
    J Ocul Pharmacol Ther; 2005 Jun; 21(3):236-41. PubMed ID: 15969641
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system.
    Ginsburg AS; Lee J; Woolwine SC; Grosset JH; Hamzeh FM; Bishai WR
    Antimicrob Agents Chemother; 2005 Feb; 49(2):853-6. PubMed ID: 15673788
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pre- and post-exposure prophylaxis of experimental Burkholderia pseudomallei infection with doxycycline, amoxicillin/clavulanic acid and co-trimoxazole.
    Sivalingam SP; Sim SH; Jasper LC; Wang D; Liu Y; Ooi EE
    J Antimicrob Chemother; 2008 Mar; 61(3):674-8. PubMed ID: 18192684
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli.
    Schaumann R; Blatz R; Beer J; Ackermann G; Rodloff AC
    J Antimicrob Chemother; 2004 Feb; 53(2):318-24. PubMed ID: 14729746
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protection of BALB/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4.
    Winter AJ; Schurig GG; Boyle SM; Sriranganathan N; Bevins JS; Enright FM; Elzer PH; Kopec JD
    Am J Vet Res; 1996 May; 57(5):677-83. PubMed ID: 8723881
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Topical ophthalmic fourth-generation fluoroquinolones: Appropriate use and cost considerations.
    Fiscella RG; Lewis CC; Jensen MK
    Am J Health Syst Pharm; 2007 Oct; 64(19):2069-73. PubMed ID: 17893419
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of the effects of fourth-generation fluoroquinolones on epithelial healing after photorefractive keratectomy.
    Shin JH; Lee HB; Park HY
    Cornea; 2010 Nov; 29(11):1236-40. PubMed ID: 20697276
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections.
    Ozdek SC; Miller D; Flynn PM; Flynn HW
    Ocul Immunol Inflamm; 2006 Dec; 14(6):347-51. PubMed ID: 17162605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.